These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 8953135)

  • 1. Use of ursodeoxycholic acid in the treatment of arteriohepatic dysplasia.
    Kay MH; Wyllie R; Steffen RM
    Clin Pediatr (Phila); 1996 Nov; 35(11):593-6. PubMed ID: 8953135
    [No Abstract]   [Full Text] [Related]  

  • 2. [Alagille syndrome diagnosed in adolescence: a case report].
    Fadlouallah M; Krami H; Tamzaourte M; Lahmiri M; Tahri S; El Koundi H; Mahassini N; Jahid A; Errabih I; Ouazzani H
    Arch Pediatr; 2010 Jul; 17(7):1111-3. PubMed ID: 20627670
    [No Abstract]   [Full Text] [Related]  

  • 3. Application of ursodeoxycholic acid (UDCA) in the therapy of liver and biliary duct diseases in children.
    Lebensztejn DM
    Med Sci Monit; 2000; 6(3):632-6. PubMed ID: 11208384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein E polymorphism in alagille syndrome and progressive familial intrahepatic cholestasis.
    Socha P; Nowicka G; Jankowska I; Rujner J; Pawłowska J; Socha J
    Dig Dis Sci; 2000 Apr; 45(4):675-9. PubMed ID: 10759233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ursodeoxycholic acid as a supplementary treatment in corrected biliary atresia.
    Smaropoulos EC; Kaselas B
    Eur J Pediatr Surg; 2006 Apr; 16(2):138-9. PubMed ID: 16685625
    [No Abstract]   [Full Text] [Related]  

  • 6. The effect of ursodeoxycholic acid in children with prolonged hepatitis A virus infection that may be a trigger factor for autoimmune hepatitis.
    Koçak N; Saltik IN
    Am J Gastroenterol; 2001 Feb; 96(2):610-1. PubMed ID: 11232728
    [No Abstract]   [Full Text] [Related]  

  • 7. Ursodeoxycholic acid in the treatment of AIDS-associated cholangiopathy.
    Castiella A; Iribarren JA; López P; Arrizabalaga J; Rodríguez F; von Wichmann MA; Arenas JI
    Am J Med; 1997 Aug; 103(2):170-1. PubMed ID: 9274905
    [No Abstract]   [Full Text] [Related]  

  • 8. Ursodeoxycholic acid for primary biliary cirrhosis.
    Lindor KD; Poupon R; Poupon R; Heathcote EJ; Therneau T
    Lancet; 2000 Feb; 355(9204):657-8. PubMed ID: 10697011
    [No Abstract]   [Full Text] [Related]  

  • 9. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis.
    Lindor K
    N Engl J Med; 2007 Oct; 357(15):1524-9. PubMed ID: 17928600
    [No Abstract]   [Full Text] [Related]  

  • 10. [Influence of ursodeoxycholic acid on the immune status of patients with cholesterosis of gall-bladder depending on cholesterol index in blood].
    Shcherbinina MB; Babets MI; Kudriavtseva VI
    Eksp Klin Gastroenterol; 2014; (1):53-8. PubMed ID: 25518458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis.
    Stiehl A
    Ital J Gastroenterol; 1996 Apr; 28(3):178-80. PubMed ID: 8789831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does prophylactic ursodeoxycholic acid treatment of liver transplant patients prevent acute rejection?
    Keiding S
    Hepatology; 1998 Jun; 27(6):1748-9. PubMed ID: 9620354
    [No Abstract]   [Full Text] [Related]  

  • 13. Recurrent intrahepatic cholestasis of pregnancy: ursodeoxycholic acid should be the first line of treatment.
    Jain P
    J Gastrointestin Liver Dis; 2008 Dec; 17(4):479-80. PubMed ID: 19104716
    [No Abstract]   [Full Text] [Related]  

  • 14. [Primary biliary cirrhosis and ursodeoxycholic acid therapy].
    Makino I
    Nihon Naika Gakkai Zasshi; 1996 Mar; 85(3):399-403. PubMed ID: 8691003
    [No Abstract]   [Full Text] [Related]  

  • 15. [The characteristics of the use of ursodeoxycholic acid in chronic diseases of the hepatobiliary system].
    Dehtiar'ova II; Chernenko VV; Anokhina HA; Opanasiuk ND; Pavlik-Novol's'kyĭ T; Haĭsenko AV
    Lik Sprava; 1995; (9-12):47-8. PubMed ID: 8983789
    [No Abstract]   [Full Text] [Related]  

  • 16. Favourable long term effect of ursodeoxycholic acid treatment on congenital vanishing bile duct syndromes.
    Karageorgos SA; Tzardi M; Stratakou S; Voumvouraki A; Notas G; Kouroumalis E
    Acta Gastroenterol Belg; 2018; 81(2):330-332. PubMed ID: 30024707
    [No Abstract]   [Full Text] [Related]  

  • 17. Pregnancy in women with ursodeoxycholic acid-treated primary biliary cirrhosis.
    Poupon R; Chrétien Y; Chazouillères O; Poupon RE
    J Hepatol; 2005 Mar; 42(3):418-9. PubMed ID: 15710226
    [No Abstract]   [Full Text] [Related]  

  • 18. A child with Kabuki syndrome and primary sclerosing cholangitis successfully treated with ursodiol and cholestryamine.
    Suskind DL; Finn L; Wahbeh G; Christie D; Horslen S
    J Pediatr Gastroenterol Nutr; 2006 Oct; 43(4):542-4. PubMed ID: 17033534
    [No Abstract]   [Full Text] [Related]  

  • 19. Ursofalk.
    Williams CN
    Can J Gastroenterol; 1999 Nov; 13(9):717-8. PubMed ID: 10633823
    [No Abstract]   [Full Text] [Related]  

  • 20. Ursodeoxycholic acid and long-term survival in primary biliary cirrhosis.
    Levy C; Angulo P
    Am J Gastroenterol; 2004 Feb; 99(2):269-70. PubMed ID: 15046216
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.